What type of study is this?

September 10, 2025Open Life SciencesOpen Access

Atractylenolide I alleviates the experimental allergic response in mice by suppressing TLR4/NF-kB/NLRP3 signalling

View Full Paper

Ask AI

Bookmark

Authors

Observational analysis reveals Atractylenolide I reduces allergic symptoms in mice, indicating TLR4/NF-kB/NLRP3 may be a therapeutic target.

ATL-I administration significantly decreased allergic responses in AR mice, reducing sneezing and rubbing frequencies.
Treatment with ATL-I led to notable decreases in serum histamine and IgE levels, indicating a reduction in inflammation.
ATL-I inhibited TLR4/NF-kB pathway activation, resulting in downregulation of inflammatory cytokines and improved immune balance.
Mice treated with ATL-I showed less mucosal thickness and reduced hyperplasia of goblet cells, showcasing tissue protection.

Cai et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational analysis reveals Atractylenolide I reduces allergic symptoms in mice, indicating TLR4/NF-kB/NLRP3 may be a therapeutic target.